Medexus Pharmaceuticals Inc, Next Green Wave Holdings Inc, Humanigen Inc,

A glance at some of the day’s highlights from the Proactive Investors US and Canada newswires

() () revealed that it has struck an agreement with Geneva, Switzerland-based Westmount Capital for it to provide European investor relations services to the Toronto-based specialty pharma company which has a portfolio of therapeutic drugs. Under the terms of the agreement, Westmount will receive C$5,000 per month for an initial trial of three months starting on November 1. After this the company will consider a possible extension. Westmount will introduce Medexus to various institutional investors, fund managers, family offices and other potential investors in Europe. 

Holdings Inc () () announced Friday that its chairman Robert Dzisiak had resigned from his position to explore new business opportunities, according to the Vancouver-based cannabis firm. In a statement, the company said that Dzisiak was “instrumental in helping guide the company through many industry challenges throughout 2020” and wished him all the best in his future endeavors. Next Green Wave did not announce a replacement for the outgoing chairman.

Humanigen Inc (NASDAQ:HGEN), which is focused on preventing and treating the immune hyper-response called ‘cytokine storm’ with lenzilumab, announced Friday that MedStar Washington Hospital Center in Washington, DC treated its first COVID-19 patient with the drug. The Burlingame, California-based company said the primary goal of this Phase 3 randomized, double-blind, multicenter, placebo-controlled clinical trial is to determine if lenzilumab can help hospitalized patients with COVID-19 recover faster. As many as 89% of hospitalized patients with COVID-19 are at risk of a complication called cytokine storm, a harmful inflammation that has been the leading cause of COVID-19 death. Humanigen noted that MedStar Washington Hospital Center is one of 18 sites in the US approved to enroll eligible patients to study lenzilumab, designed specifically to stop this storm. Eligible patients can participate in this trial while also receiving other standard-of-care therapies as recommended by their treating physician.

Canada Silver Cobalt Works () (OTCQB:CCWOF) struck a deal with MagNor Resources on Friday to earn 100% interest in the latter’s B2 property in Quebec. B2 consists of 12 claims totaling 670 hectares in the Lac-St-Jean region of Quebec. Mineralization is traceable along strike over one kilometre and open in all directions, according to CCW. Samples taken from the property were assayed and returned results showing massive nickel-copper-cobalt mineralization, with grades of up to 1.1% nickel, 0.6% copper and 0.2% cobalt.

() reported another profitable quarter that saw the infrastructure company deliver $128,000 in net income, according to third-quarter results released Friday. The results are a sharp contrast to the period…

Read More:Source link